Join
Live feed
·
PRReleasevia Quantisnow
BeiGene Ltd. logo

BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

ByQuantisnow·Wall Street's wire, on your screen.
BGNE· BeiGene Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BGNE (BeiGene Ltd.) and more on Quantisnow.